Publications by authors named "Ekaterina V Chernyaeva"
Proposed rituximab biosimilar BCD-020 versus reference rituximab for treatment of patients with indolent non-Hodgkin lymphomas: An international multicenter randomized trial.
Irina V Poddubnaya Sergey M Alekseev Kamil D Kaplanov Les M Lukavetskyy Grigoriy B Rekhtman Ekaterina V Chernyaeva
Hematol Oncol
February 2020
Article Synopsis
- BCD-020 is a proposed biosimilar to rituximab, demonstrating similar quality and effectiveness in treating adult patients with indolent lymphomas in a multicenter clinical trial.
- The study involved 174 patients, showing overall response rates of 44.71% for BCD-020 and 41.89% for rituximab, indicating equivalent efficacy between the two treatments.
- Both drugs had comparable safety profiles, with no unexpected adverse reactions and similar patterns in the depletion of B-cells, confirming pharmacokinetic equivalence.
BCD-055 is a biosimilar of innovator infliximab (IFX). Here we present the 54-week results from phase 3 clinical study in patients with rheumatoid arthritis (RA). The aim of this study was to demonstrate the equivalent efficacy and safety of BCD-055 and IFX in patients with active rheumatoid arthritis.
View Article and Find Full Text PDF